NCT05111743

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 9,261 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This study was a retrospective cohort study of patients to assess the early insights into real-world safety among wet AMD patients initiating brolucizumab. Evidence was generated to describe their patient characteristics and clinical outcomes. The study was conducted using the Komodo Healthcare Map.

Detailed description

Komodo Healthcare Map claims data from 08-Oct-2016 to the date of most recent data from patients with wet AMD who initiated brolucizumab were analyzed in this study. * Identification period of the index date (index period): The patients fulfilling the selection criteria were identified during the period from 08-Oct-2019 to 30-Apr-2020. * Index date: Defined as the date of the earliest brolucizumab injection during the index period. * Study Period: The period from 08-Oct-2016 to the most recent data extraction date (05-Jun-2020). o Note since 05-Jun-2020 was the date data was pulled, claims data from recent months (e.g. May) may be incomplete (relative to the final DB state) as well. * Pre-index period: The period 36 months prior to the index date o Note: Data within 36 months prior to the index date will be used to assess baseline characteristics. * Post-index period: The period of 180 days after the index date

Conditions

• Age-related Macular Degeneration (AMD)

Interventions

Type	Name	Description
DRUG	Brolucizumab	Participants received brolucizumab injection during the index period

Timeline

• Start date: 2020-06-17
• Primary completion: 2020-12-18
• Completion: 2020-12-18
• First posted: 2021-11-08
• Last updated: 2021-12-21

Locations

1 site across 1 country: United States